Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)

被引：0
|
作者：
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] Brown Univ, Legorreta Canc Ctr, Lifespan Canc Inst, Providence, RI USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
[10] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[11] Penn State Univ, Coll Med, Hershey, PA USA
[12] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7021
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
  • [42] Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma
    Leveille, Etienne
    Kothari, Shalin
    Cosgun, Kadriye N.
    Mlynarczyk, Coraline
    Mueschen, Markus
    CANCER DISCOVERY, 2024, 14 (09) : 1577 - 1580
  • [43] Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Camus, Vincent
    Tilly, Herve
    FUTURE ONCOLOGY, 2020, 17 (02) : 127 - 136
  • [44] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Hajime Yasuda
    Naoko Kaga
    Hikari Taka
    Tomonori Ochiai
    Tomohito Yamana
    Yoshiki Miura
    Midori Ishii
    Makoto Sasaki
    Jun Ando
    Miki Ando
    Cancer Chemotherapy and Pharmacology, 2024, 93 (3) : 265 - 268
  • [45] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Yasuda, Hajime
    Kaga, Naoko
    Taka, Hikari
    Ochiai, Tomonori
    Yamana, Tomohito
    Miura, Yoshiki
    Ishii, Midori
    Sasaki, Makoto
    Ando, Jun
    Ando, Miki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 265 - 268
  • [46] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hirata, Jamie
    Perretti, Thomas
    Musick, Lisa
    McMillan, Andrew K.
    BLOOD, 2021, 138
  • [47] Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
    Corcoran, Sean R.
    Phelan, James D.
    Choi, Jaewoo
    Shevchenko, Galina
    Fenner, Rachel E.
    Yu, Xin
    Scheich, Sebastian
    Hsiao, Tony
    Morris, Vivian M.
    Papachristou, Evangelia K.
    Kishore, Kamal
    D'Santos, Clive S.
    Ji, Yanlong
    Pittaluga, Stefania
    Wright, George W.
    Urlaub, Henning
    Pan, Kuan-Ting
    Oellerich, Thomas
    Muppidi, Jagan
    Hodson, Daniel J.
    Staudt, Louis M.
    CANCER DISCOVERY, 2024, 14 (09) : 1653 - 1674
  • [48] Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Ghione, Paola
    Salles, Gilles
    HAEMATOLOGICA, 2024, 109 (09) : 2802 - 2809
  • [49] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Dal, Mehmet Sinan
    Ulu, Bahar Uncu
    Uzay, Ant
    Akay, Olga Meltem
    Besisik, Sevgi
    Yenerel, Mustafa Nuri
    Celik, Serhat
    Kaynar, Leylagul
    Yucel, Orhan Kemal
    Deveci, Burak
    Sonmez, Mehmet
    Mehtap, Ozgur
    Bekoz, Huseyin Saffet
    Sunu, Cenk
    Salim, Ozan
    Ulas, Turgay
    Karti, Sami
    Altuntas, Fevzi
    Ferhanoglu, Burhan
    Tuglular, Tulin Firat
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 133 - 140
  • [50] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
12345